



NIPM-QCDR 2021 QCDR Measure Detail

January 2021






Contents

NIPM18: CHANGE IN PATIENT REPORTED QUALITY OF LIFE FOLLOWING EPIDURAL LYSIS OF ADHESIONS 3	
NIPM19: CHANGE IN PATIENT REPORTED QUALITY OF LIFE AND FUNCTIONAL STATUS FOLLOWING MEDIAL BRANCH RADIOFREQUENCY ABLATION	
NIPM20: CHANGE IN PATIENT REPORTED PAIN AND FUNCTIONAL STATUS FOLLOWING SPINAL CORD STIMULATOR IMPLANTATION	,
NIPM22: CHANGE IN PATIENT REPORTED QUALITY OF LIFE FOLLOWING EPIDURAL CORTICOSTEROID INJECTION6	
NIPM23: CHANGE IN PATIENT REPORTED QUALITY OF LIFE FOLLOWING MAJOR JOINT CORTICOSTEROID INJECTION7	
NIPM24: CHANGE IN PATIENT REPORTED QUALITY OF LIFE FOLLOWING INTRATHECAL PUMP IMPLANTATION	
NIPM25: CHANGE IN PATIENT REPORTED QUALITY OF LIFE FOLLOWING INTERSPINOUS INDIRECT DECOMPRESSION (SPACER)	,





NIPM18: CHANGE IN PATIENT REPORTED QUALITY OF LIFE FOLLOWING EPIDURAL LYSIS OF ADHESIONS

Measurement Period: January 1, 2021 to December 31, 2021

Measure Developer: American Society of Interventional Pain Physicians

Description: Measurement of the change in patient-reported quality of life following epidural lysis of adhesions. Quality-of-life measurement on standardized scale includes pain, mobility, analgesic medication use, and activities of daily living.

Disclaimer: These performance measures are not standards and do not establish a standard of medical care.

NQS Domain: Person and Caregiver Centered Experience and Outcomes Measure Type: Patient Reported Outcome (PRO) Meaningful Measure Area: Functional Outcomes Risk Adjustment: None Performance rate: 1 Inverse Measure: No Care Setting: Ambulatory Care: Clinician Office/Clinic

Denominator: All patients 18 years and older who undergo epidural lysis of adhesions. ANY of the following CPT Codes: 62263, 62264


Denominator Exclusions: Patients who choose to not provide consent or participate in patient-reported outcome surveys.

(NOTE: Provider reporting and performance rates will only include those patients who respond to the surveys).

Denominator Exceptions: Patients who are within the patient-reported outcome reporting window, but for whom the reporting year ends prior to their responding to the survey.

Numerator: Improvement in quality of life on a standardized scale (including pain, mobility, analgesic medication use, and activities of daily living), as reported by the patient between 3-6 weeks following the procedure.





NIPM19: CHANGE IN PATIENT REPORTED QUALITY OF LIFE AND FUNCTIONAL STATUS FOLLOWING MEDIAL BRANCH RADIOFREQUENCY ABLATION

Measurement Period: January 1, 2021 to December 31, 2021

Measure Developer: American Society of Interventional Pain Physicians

Description: Measurement of the change in patient reported quality of life following medial branch radiofrequency ablation. Quality of life measurement on standardized scale includes mobility, analgesic medication use, psychological well-being and activities of daily living.

Disclaimer: These performance measures are not standards and do not establish a standard of medical care.

NQS Domain: Person and Caregiver Centered Experience and Outcomes Measure Type: Patient Reported Outcome (PRO) Meaningful Measure Area: Functional Outcomes Risk Adjustment: None Performance rate: 2 (cervical/thoracic, lumbar/sacral) Inverse Measure: No Care Setting: Ambulatory Care: Clinician Office/Clinic

Denominator: All patients aged 18 years and older who undergo medial branch radiofrequency ablation. ANY of the following CPT codes in the same encounter: 64633, 64634, 64635, 64636

Denominator Exclusions: Patients who choose to not provide consent or participate in patient-reported outcome surveys.

(NOTE: Provider reporting and performance rates will only include those patients who respond to the surveys).

Denominator Exceptions: Patients who are within the 120-day patient-reported outcome window, but for whom the reporting year ends prior to their responding to the survey.

Numerator: Improvement in quality of life on a standardized scale (including mobility, analgesic medication use, psychological well-being and activities of daily living), as reported by the patient within 120 days following the procedure.



NIPM20: CHANGE IN PATIENT REPORTED PAIN AND FUNCTIONAL STATUS FOLLOWING SPINAL CORD STIMULATOR IMPLANTATION

Measurement Period: January 1, 2021 to December 31, 2021

Measure Developer: American Society of Interventional Pain Physicians

Description: Measurement of the change in patient reported quality of life following spinal cord stimulator implantation for failed back surgery syndrome. Quality of life measurement on standardized scale includes pain, mobility, analgesic medication use, psychological well-being and activities of daily living.

Disclaimer: These performance measures are not standards and do not establish a standard of medical care.

NQS Domain: Person and Caregiver Centered Experience and Outcomes Measure Type: Patient Reported Outcome (PRO) Meaningful Measure Area: Functional Outcomes Risk Adjustment: None Performance rate: 1 Inverse Measure: No Care Setting: Ambulatory Care: Hospital

Denominator: All patients aged 18 years and older who undergo surgical implantation of a spinal cord stimulator with implantable pulse generator, excluding replacement or revision of existing spinal cord stimulation systems. ALL of the following CPT Codes in the same encounter: 63650, 63685

Denominator Exclusions:

- Patients undergoing revision or replacement of pulse generator: 63688
- Patients undergoing temporary placement of neuroelectrodes: 63650 without 63685
- Patients undergoing revision or replacement of existing neuroelectrodes: 63663
- Patients who choose to not provide consent or participate in patient-reported outcome surveys.


(NOTE: Provider reporting and performance rates will only include those patients who respond to the surveys).

Denominator Exceptions: Patients who are within the 120-day patient-reported outcome window, but for whom the reporting year ends prior to their responding to the survey.

Numerator: Improvement in pain and quality of life on a standardized scale (including mobility, analgesic medication use, psychological well-being and activities of daily living), as reported by the patient within 120 days following the procedure.

Numerator Exclusions: Patients in whom the neuroelectrodes and/or pulse generator were revised or explanted during the 120-day post-operative period: 63661, 63663, 63688





Continuous Variable: Yes (0-100) Priority Status: High

NIPM22: CHANGE IN PATIENT REPORTED QUALITY OF LIFE FOLLOWING EPIDURAL CORTICOSTEROID INJECTION

Measurement Period: January 1, 2021 to December 31, 2021

Measure Developer: American Society of Interventional Pain Physicians

Description: Measurement of the change in patient reported quality of life following caudal, lumbar, thoracic, or cervical epidural corticosteroid injection. Quality of life measurement on standardized scale includes pain, mobility, psychological well-being, analgesic medication use, and activities of daily living.

Disclaimer: These performance measures are not standards and do not establish a standard of medical care.

NQS Domain: Person and Caregiver Centered Experience and Outcomes Measure Type: Patient-Reported Outcome (PRO) Meaningful Measure Area: Functional Outcomes Risk Adjustment: None Performance rate: 2 (cervical/thoracic, lumbar/sacral) Inverse Measure: No Care Setting: Ambulatory Care: Clinician Office/Clinic

Denominator: All patients 18 years and older who undergo epidural corticosteroid injection(s) through an interlaminar, transforaminal or caudal approach. ANY of the following CPT Codes: 62320, 62321, 62322, 62323, 64479, 64480, 64483, 64484

Denominator Exclusions: Patients who choose to not provide consent or participate in patient-reported outcome surveys.

(NOTE: Provider reporting and performance rates will only include those patients who respond to the surveys).

Denominator Exceptions: Patients who are within the patient-reported outcome reporting window, but for whom the reporting year ends prior to their responding to the survey.

Numerator: Improvement in quality of life on a standardized scale (including pain, mobility, analgesic medication use, and activities of daily living), as reported by the patient between 3-6 weeks following the injection(s).



NIPM23: CHANGE IN PATIENT REPORTED QUALITY OF LIFE FOLLOWING MAJOR JOINT CORTICOSTEROID INJECTION

Measurement Period: January 1, 2021 to December 31, 2021

Measure Developer: American Society of Interventional Pain Physicians

Description: Measurement of the change in patient reported quality of life following major corticosteroid injection. Quality of life measurement on standardized scale includes pain, mobility, analgesic medication use, and activities of daily living.

Disclaimer: These performance measures are not standards and do not establish a standard of medical care.

NQS Domain: Person and Caregiver-Centered Experience and Outcomes Measure Type: Patient Reported Outcome (PRO) Meaningful Measure Area: Functional Outcomes Risk Adjustment Variable: None Performance rate: 1 Inverse Measure: No Care Setting: Ambulatory Care: Clinician Office/Clinic

Denominator: All patients 18 years and older who undergo sacroiliac joint corticosteroid injection(s) or major joint corticosteroid injections.

ANY of the following CPT Codes: 27096, G0260 (SI joint) OR ANY of the following CPT Codes: 20610 (hip, knee, shoulder, subacromial bursa)


Denominator Exclusions: Patients who choose to not provide consent or participate in patient-reported outcome surveys.

(NOTE: Provider reporting and performance rates will only include those patients who respond to the surveys).

Denominator Exceptions: Patients who are within the patient-reported outcome reporting window, but for whom the reporting year ends prior to their responding to the survey.

Numerator: Improvement in quality of life on a standardized scale (including pain, mobility, analgesic medication use, and activities of daily living), as reported by the patient between 3-6 weeks following the injection(s).





NIPM24: CHANGE IN PATIENT REPORTED QUALITY OF LIFE FOLLOWING INTRATHECAL PUMP IMPLANTATION

Measurement Period: January 1, 2021 to December 31, 2021

Measure Developer: American Society of Interventional Pain Physicians

Description: Measurement of the change in patient reported quality of life following intrathecal pump implantation. Quality of life measurement on standardized scale includes pain, mobility, psychological well-being, and activities of daily living.

Disclaimer: These performance measures are not standards and do not establish a standard of medical care.

NQS Domain: Person and Caregiver-Centered Experience and Outcomes Measure Type: Patient Reported Outcome (PRO) Meaningful Measure Area: Functional Outcomes Risk Adjustment Variable: None Performance rate: 1 Inverse Measure: No Care Setting: Ambulatory Care: Hospital

Denominator: All patients aged 18 years and older who undergo surgical implantation of an intrathecal drug infusion system, excluding replacement or revision of an existing system.

ALL of the following CPT Codes in the same encounter: 62350, 62362

Denominator Exclusions: Patients undergoing revision or replacement of an intrathecal drug infusion system. Patients who choose to not provide consent or participate in patient-reported outcome surveys.

(NOTE: Provider reporting and performance rates will only include those patients who respond to the surveys).

Denominator Exceptions: Patients who are within the 120-day patient-reported outcome window, but for whom the reporting year ends prior to their responding to the survey.

Numerator: Improvement in pain and quality of life on a standardized scale (including mobility, psychological well-being and activities of daily living), as reported by the patient within 120 days following the procedure.

Numerator Exclusions: Patients in whom the neuroelectrodes and/or pulse generator were revised or explanted during the 120-day post-operative period: 63661, 63663, 63688 Continuous Variable: Yes (0-100) Priority Status: High



NIPM25: CHANGE IN PATIENT REPORTED QUALITY OF LIFE FOLLOWING INTERSPINOUS INDIRECT DECOMPRESSION (SPACER)

Measurement Period: January 1, 2021 to December 31, 2021

Measure Developer: American Society of Interventional Pain Physicians

Description: Measurement of the change in patient reported quality of life following interspinous indirect decompression (spacer). Quality of life measurement on standardized scale includes pain, mobility, psychological well-being, analgesic medication use, and activities of daily living.

Disclaimer: These performance measures are not standards and do not establish a standard of medical care.

NQS Domain: Person and Caregiver-Centered Experience and Outcomes Measure Type: Patient Reported Outcome (PRO) Meaningful Measure Area: Functional Outcomes Risk Adjustment Variable: None Performance rate: 1 Inverse Measure: No Care Setting: Ambulatory Care: Hospital

Denominator: All patients 18 years and older who undergo interspinous indirect decompression (spacer). ANY of the following CPT Codes: 22869, 22870

Denominator Exclusions: Patients undergoing revision or replacement of interspinous spacer within 120 days of the initial procedure.

Patients who choose to not provide consent or participate in patient-reported outcome surveys.

(NOTE: Provider reporting and performance rates will only include those patients who respond to the surveys).

Denominator Exceptions: Patients who are within the patient-reported outcome reporting window, but for whom the reporting year ends prior to their responding to the survey.

Numerator: Improvement in pain and quality of life on a standardized scale (including mobility, analgesic medication use, psychological well-being and activities of daily living), as reported by the patient within 120 days following the procedure.